4月2日,亿胜生物科技公布有关与复宏汉霖就渗出性(湿性)老年性黄斑部病变治疗三期临床研究达到主要研究终点。内容有关受许人(均为亿胜生物科技的全资附属公司)与上海复宏汉霖生物技术股份有限公司(“复宏汉霖”)订立共同开发许可协议,以根据共同开发许可协议的条款共同开发许可产品及向受许人授出有关许可产品的独家权利。兹亦提述亿胜生物科技于2021年1月至2025年1月期间刊发的若干公布,内容有关上述事项的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.